Evoke Pharma 将来の成長

Future 基準チェック /56

Evoke Pharmaは、117.2%と55%でそれぞれ年率117.2%で利益と収益が成長すると予測される一方、EPSはgrowで114.6%年率。

主要情報

117.2%

収益成長率

114.6%

EPS成長率

Pharmaceuticals 収益成長	21.2%
収益成長率	55.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	28 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:EV0 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	32	8	N/A	N/A	1
12/31/2025	20	1	N/A	N/A	1
12/31/2024	11	-5	N/A	N/A	1
6/30/2024	8	-7	-6	-6	N/A
3/31/2024	6	-7	-6	-6	N/A
12/31/2023	5	-8	-5	-5	N/A
9/30/2023	4	-8	-6	-6	N/A
6/30/2023	4	-8	-6	-6	N/A
3/31/2023	3	-8	-7	-7	N/A
12/31/2022	3	-8	-7	-7	N/A
9/30/2022	2	-8	-6	-6	N/A
6/30/2022	2	-8	-11	-11	N/A
3/31/2022	2	-8	-11	-11	N/A
12/31/2021	2	-9	-12	-12	N/A
9/30/2021	1	-9	-12	-12	N/A
6/30/2021	0	-9	-8	-8	N/A
3/31/2021	0	-14	-8	-8	N/A
12/31/2020	0	-13	-7	-7	N/A
9/30/2020	N/A	-12	-6	-6	N/A
6/30/2020	N/A	-12	-5	-5	N/A
3/31/2020	N/A	-7	-5	-5	N/A
12/31/2019	N/A	-7	-6	-6	N/A
9/30/2019	N/A	-7	-6	-6	N/A
6/30/2019	N/A	-7	-6	-6	N/A
3/31/2019	N/A	-8	-6	-6	N/A
12/31/2018	N/A	-8	-7	-7	N/A
9/30/2018	N/A	-6	-8	-8	N/A
6/30/2018	N/A	-10	-10	-10	N/A
3/31/2018	N/A	-9	N/A	-10	N/A
12/31/2017	N/A	-12	N/A	-9	N/A
9/30/2017	N/A	-13	N/A	-7	N/A
6/30/2017	N/A	-11	N/A	-8	N/A
3/31/2017	N/A	-13	N/A	-8	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-10	N/A
6/30/2016	N/A	-12	N/A	-10	N/A
3/31/2016	N/A	-12	N/A	-10	N/A
12/31/2015	N/A	-12	N/A	-10	N/A
9/30/2015	N/A	-12	N/A	-11	N/A
6/30/2015	N/A	-14	N/A	-12	N/A
3/31/2015	N/A	-14	N/A	-12	N/A
12/31/2014	N/A	-13	N/A	-12	N/A
9/30/2014	N/A	-12	N/A	-11	N/A
6/30/2014	N/A	-9	N/A	-7	N/A
3/31/2014	N/A	-5	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EV0は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.8% ) よりも高い成長率であると考えられます。

収益対市場: EV0今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EV0今後 3 年以内に収益を上げることが予想されます。

収益対市場: EV0の収益 ( 55% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: EV0の収益 ( 55% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EV0の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Evoke Pharma 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023)

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.67 loss in 1Q 2023)

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.60 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$2.62 loss per share (vs US$3.18 loss in FY 2021)

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.73 loss in 3Q 2021)

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.85 loss in 2Q 2021)

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma, Inc. Announces the Launch of Wave 1 of an Innovative Social Media Campaign to Reach Patients Directly with Education About Diabetic Gastroparesis

Independent Director has left the company

No longer forecast to breakeven

Revenue misses expectations

Evoke Pharma, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: €2.00

Evoke Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

Evoke Pharma, Inc. Announces, Through its Marketing Partner, Eversana Life Science Services, LLC, Conducted an ATU (Awareness, Trial, and Usage) Study, Quantitative Survey to Measure Physician Awareness, Trial, and Product Usage, for GIMOTI

New 90-day low: €2.07

Co-Founder recently sold €173k worth of stock

New 90-day low: €2.37

New 90-day low: €2.70

New 90-day low: €3.26

Evoke Pharma, Inc. and Eversana Life Science Services, LLC Announce Commercial Launch of Gimoti™

New 90-day high - €3.60

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想